BISPECIFIC ANTI‐CD20/19 CAR‐T—ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL—INTERIM ANALYSIS RESULTS OF DALY‐II‐USA STUDY
作者
Matthew L. Ulrickson,David Bernard Miklos,Richard Thomas Maziarz,Caron Alyce Jacobson,Iris Isufi,Monalisa Ghosh,Miguel‐Angel Perales,Matthew Alexander Lunning,Nancy M. Hardy,Anna Wijatyk,Marek Ancukiewicz,Mrs. Madhavi Nallewar,K. C. Coleman,Bethany Cheree Prudner,Esther Eromosele,Remiguisz Kaleta,Nirav Niranjan Shah
Background: DALY II USA is the first multicenter trial of fresh, bispecific targeted CD20/CD19, chimeric antigen receptor (CAR) T-cell therapy for patients (pts) with R/R diffuse large B-cell lymphoma (DLBCL). While CD19 CAR T-cell therapy is an established treatment for pts with R/R DLBCL, relapse remains a clinical challenge. One proposed mechanism of resistance is either loss of epitope, recognition, or downregulation of the CD19 receptor. To improve outcomes, dual targeting of B-cell receptors has been proposed. Reported here is the preplanned interim futility analysis after treatment of 22 evaluable pts. Aim: To assess safety and efficacy of dual CAR-T therapy with zamtocabtagene autoleucel (zamto-cel) administered fresh in R/R DLBCL. Methods: Eligible pts were >18 y, ECOG PS 0–1, with R/R DLBCL after ≥2 prior lines of systemic therapy. No bridging chemotherapy was allowed. Apheresis material was shipped fresh without cryopreservation to a central manufacturing site. A fixed 12-day process of CAR-T production was performed using the CliniMACS Prodigy® (Miltenyi Biotec). A single infusion of 2.5x106 cells/kg fresh zamto-cel was administered after lymphodepletion which was initiated during manufacturing to facilitate a fresh infusion. Evaluation of response rate is the primary objective of this study. Results: As of 1 September 2022, 28 pts have enrolled (All treated) with 22 evaluable per protocol. Most (69%) of treated patients presented advanced disease with IPI score of at least 3 and abnormal baseline LDH and 28% were previously treated with CD19 and or CD79 targeting agents. Six pts were not included in the primary efficacy analysis. One received a frozen product and 5 received a non-conforming fresh product. Per Independent Radiology Committee (IRC) 18 (82%) of 22 evaluable pts had either complete (CR—46%) or partial response (PR—36%) exceeding the preplanned futility threshold. The response rate in the evaluable set was similar to that in the all-treated population (Tbl. 1). Post-progression biopsies were available in 5 pts. There was no isolated CD19 loss, but 1pt had dual target loss CD19+CD20 in relation to the pre-treatment status. PFS at 6 months for evaluable pts was 64% and 61% for all treated. The treatment was well tolerated. Among all 28 treated pts., there were no grade 3–4 CRS events and only two transient and reversible Grade 3 ICANS (9%). There was no treatment-related mortality. Summary/Conclusion: The prespecified efficacy threshold of zamto-cel was exceeded in the interim analysis Treatment demonstrated a favorable safety profile, with promising ORR and PFS in advanced DLBCL population often pre-treated with agents not available in previous similar studies. We also demonstrate the feasibility of a rapid manufacturing process with 100% fresh infusion in eligible pts. Encore Abstract—previously submitted to EHA 2023 Keywords: aggressive B-cell non-Hodgkin lymphoma, cellular therapies, immunotherapy No conflicts of interests pertinent to the abstract.